

**Connecticut Dermatology and  
Dermatologic Surgery Society  
January/February 2021 Education Series**



**Registration  
January 21, 28, February 4, 2021**

**Exhibit Rooms Available Each Day**

# AGENDA

## Thursday January 21 – Moderator: Omar Ibrahimi, M.D.

6:00 pm **Business Meeting**

6:45 pm **“Diversity In Dermatology: Moving the Needle” – Mona Gohara, M.D.**

*Objectives: 1. Learn to identify different types of unconscious bias 2. Learn ways to move the needle as it pertains to DEI in dermatology.*

7:15 pm **“Legal Issues in Dermatology” – Matthew Avram, M.D.**

*Objectives: 1. To understand basic legal terms regarding medical practice and liability 2. To understand how basic legal concepts apply to medical, surgical and cosmetic dermatology*

7:45 pm **“Don’t Miss it! – Rare but Important Pediatric Skin Conditions” – Jennifer Huang, M.D.**

*Objectives: 1. To identify malignant causes of neonatal purpura. 2. To develop a systematic process in the evaluation of a diaper rash. 3. To recognize infectious causes of mucocutaneous hypersensitivity reactions.*

8:45 pm **Exhibit Hall and Door Prizes**

## Thursday January 28 – Moderator: Jeremy Moss, M.D.

7:15 pm **“An Update on the Treatment of Vitiligo” – David Rosmarin, M.D.**

*Objectives: 1. To better understand common presentations of vitiligo in our patients. 2. To understand the current therapeutic hierarchy for treating vitiligo and also emerging pipeline therapies.*

### *Sponsored Break - Pfizer\**

8:15 pm **“An Update on a Steroid-Free Topical Option for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months and Older” – Lawrence Eichenfield, M.D.\***

*Objective: Review an Update on a Steroid-Free Topical Option for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months and Old*

9:00 pm **Exhibit Hall and Door Prizes**

## Thursday February 4 – Moderator: Mona Shahriari, M.D.

6:00 pm **“Update on Psoriasis Therapies” – Bruce Strober, M.D.**

*Objectives: 1. Discuss the emerging data on novel psoriasis therapeutics 2. Discuss new mechanisms of action for treating psoriatic skin disease 3. Discuss new indications for established therapeutics for psoriasis*

6:30 pm **“How to Get Rid of Difficult Patients and their Records” – Joyce Lagnese, JD**

*Objectives: 1. This talk will begin with the difficult patient and effective ways to terminate the physician patient relationship, including what to do with their records. . To review the medical records laws and how to dispose of records when retiring or leaving the state.*

7:00 pm **“New Anti-infectives and Why We Need Them” – Ted Rosen, M.D.**

*Objectives: At the conclusion of this activity, the participant will be able to: 1. Appreciate the depth and breadth of resistance to current anti-infectives 2. Integrate the newest anti-infective drugs into daily clinical practice 3. Appreciate new medications recently approved for obscure diseases*

8:00 pm **Adjournment**

### *Sponsored Talk in Vendor Hall - Abbvie\**

8:30 pm **“Clear Confidence – A Closer Look at Skyrizi” – Bruce Strober, M.D.\***

*Objectives: 1. Provide an update on the IL 23 class for the treatment of Psoriasis 2. Gain a clearer understanding of the clinical data for Skyrizi*

9:00 pm **“Hidradenitis Suppurativa – Piecing it Together” – Michael Payette, M.D.\***

*Objectives: 1. Completing the Patient Picture to Identify HS and Support Patient Care 2. Gain understanding of current treatment options for patients with moderate to severe HS*

## Moderator Bios



### **Omar Ibrahim, M.D.**

Dr. Omar Ibrahim is the medical director of the Connecticut Skin Institute. He completed his Dermatology training at Harvard Medical School and a fellowship program in Mohs and Reconstructive Surgery, Laser and Cosmetic Surgery at the University of California – Davis. He is well known nationally having been an invited speaker at numerous national meetings, and written extensively about Mohs Surgery, Laser and Cosmetic Procedures. Dr. Ibrahim has published over 65 research articles and book chapters on skin cancer surgery, laser and cosmetic procedures in leading medical journals. He has also performed thousands of cases of Mohs Surgery and Laser and Cosmetic procedures. Dr. Ibrahim previously served as a Visiting Assistant Professor of Dermatology at Harvard Medical School in the Wellman Center for Photomedicine. The Wellman Center for Photomedicine is the world's leading research center where the majority of today's laser and cosmetic technologies were invented and tested. He is an active participant in many clinical trials of new technologies.



### **Jeremy Moss, M.D.,**

Dr. Moss earned his bachelor's degree, graduating with distinction, from Stanford University in Stanford, California. He then went on to New York University in New York City for his medical degree. While at NYU, Dr. Moss also completed his PhD in microbiology and immunology. He did his dermatology residency at Yale University and also did fellowship work in Immunology at Yale after finishing residency. He is now both the medical director of and a physician at Brookside dermatology Associates in Bridgeport CT. Dr. Moss is a recognized leader in the field of dermatology and has been invited to speak at numerous scientific meetings. He has been published in multiple peer-reviewed research journals and has participated in more than 40 clinical trials for dermatologic medications. Dr. Moss is the President of the Connecticut Dermatology and Dermatologic Surgery Society.



### **Mona Shahriari, M.D.**

Dr. Shahriari earned her undergraduate degree from the University of Connecticut where she graduated Summa Cum Laude as an Honors Program Scholar. She went on to earn her medical degree from the University of Connecticut and developed a strong interest in dermatology during this time. After spending a year at Baystate medical center completing her internship in internal medicine, she returned to the University of Connecticut to complete her residency in Dermatology where she served as Chief resident. Prior to co-founding Central Connecticut Dermatology, Dr. Shahriari was assistant professor of dermatology and associate director of the clinical trials unit at the University of Connecticut Department of Dermatology. She is board certified by the American Board of Dermatology and a Fellow of the American Academy of Dermatology.

Dr. Shahriari's clinical and research interests include inflammatory skin conditions and the study of novel therapeutics for skin disease. Her clinical focus includes psoriasis and eczema, in particular treatment regimens utilizing biologics (i.e Dupilumab®, Humira®, Stelara®, Cosentyx®, Taltz®, Siliq®, Tremfya®, Cimzia®, Ilumya®, Skyrizi®). She has served as principle investigator and sub-investigator for numerous multi-center clinical studies, published articles in well renowned peer-reviewed journals and served as an invited speaker at local and national conferences. She is also the President of the Connecticut Society of Dermatology and Dermatologic Surgery.

## Speaker Bios



**Mathew M. Avram, M.D., J.D.** is director of the Mass General Dermatology Laser & Cosmetic Center and director of Dermatologic Surgery at MGH. Dr. Avram is Faculty Director for Procedural Training in the Department of Dermatology and is Associate Professor of Dermatology at Harvard Medical School.

Dr. Avram attended college at Princeton University and completed his dermatology residency training at Harvard, where he served as chief resident. Subsequently, he completed his Mohs micrographic surgery, laser & cosmetics fellowship at UCLA.

Dr. Avram serves as the President of the American Society for Laser Medicine & Surgery (ASLMS) for 2017-2018. ASLMS has more than 4,000 physicians, scientists and others among its membership. Elected as Treasurer of the American Society for Dermatologic Surgery (ASDS), he also serves on their Executive Committee. Dr. Avram was the recipient of the ASLMS 2015 Annual Leon Goldman Award for excellence in research, patient care and education. In, 2016, he was recipient of the ASLMS Annual Ellet Drake Award for innovation in laser surgery.

Dr. Avram has co-authored or edited six textbooks and published more than 50 peer-reviewed publications including the New England Journal of Medicine, The Journal of the Academy of Dermatology, JAMA Dermatology, Lasers in Surgery and Medicine, and Dermatologic Surgery. He has chaired 23 national meetings and has delivered more than 500 invited lectures.

Dr. Avram is an expert in laser surgery, aesthetic dermatologic procedures such as Botox, dermal (facial) fillers, and dermatologic surgery. Boston Magazine has selected Dr. Avram as one of Boston's Top Dermatologists. He is a frequent guest on the Dr. Oz show, ABC, NBC, CBS, FOX and has appeared multiple times in the New York Times, Wall Street Journal, Washington Post, and numerous other media.



### **Mona Gohara, M.D.**

Mona Gohara is a medical dermatologist in private practice. She holds a faculty appointment in the Department of Dermatology at Yale School of Medicine.

Dr. Gohara has a special interest in skin of color, and the topic of diversity in dermatology.

Mona Chairs the Diversity Committee for both the ASDS and WDS.



### **Jennifer Huang, M.D.**

Dr. Jennifer Huang is a board certified Pediatric Dermatologist who has a special interest in taking care of dermatologic conditions of children with cancer. She completed her fellowship at Boston Children's Hospital in 2011.

Dr. Huang is an Associate Professor of Dermatology, Harvard Medical School, Her clinical and research interests are in graft-versus host disease, cutaneous reactions to cancer therapies and secondary skin cancer after cancer therapy. She is also dedicated to the teaching and mentorship of trainees, and currently serves as the Program Director of the Harvard Combined Dermatology Residency Program.



**Joyce A. Lagnese, J.D.**

Ms. Lagnese is one of the founding principals of the Hartford Law firm of DanaherLagnese, PC, where she serves as head of the Medical Malpractice Defense Unit. She is a high honors graduate from the State University of New York and obtained her law degree with honors in 1980 from Hofstra University School of Law. Her practice concentration is high exposure medical practice defense litigation. For over three decades, she has defended medical malpractice cases throughout Connecticut on behalf of physicians from every medical specialty, and has successfully tried to verdict a large number of medical malpractice cases including claims of wrongful death and permanent injury. Her practice also includes representation of medical practitioners and institutions in administrative proceedings before the Connecticut Department of Public Health.

Ms. Lagnese has been an invited lecturer and Keynote Speaker to various local and regional medical societies, physicians organizations and hospitals on medico-legal topics and is co-author of a textbook on Connecticut Medical Malpractice. She has also been an advocate in the Connecticut State Legislature for malpractice tort reform.

**Ted Rosen, M.D.**

Dr. Rosen is a native of Chicago. After attending Michigan State University as a National Merit Scholar, Dr. Rosen graduated from the University of Michigan Medical School cum laude. He trained in internal medicine at the University of Alabama and in dermatology at Baylor College of Medicine, where he currently serves as Professor and Vice-Chair of Dermatology and Chief of Dermatology at the Houston Veterans Affairs Medical Center. Dr. Rosen previously served a term on the Board of Directors and is a past Vice-President of the American Academy of Dermatology. He was the 2017 recipient of the AAD Thomas G. Pearson Memorial Award for lifelong achievement in education, and the 2019 recipient of Baylor's prestigious Master Clinician award. Dr. Rosen has written over 300 peer-reviewed journal articles, 26 textbook chapters and 4 textbooks. He has been a visiting professor at over 75

university training programs and a plenary speaker for many city, state, national and international organizations, including the national dermatology societies of Canada, Mexico, Argentina, Chile, Hong Kong, Korea, China, Italy, Australia and New Zealand. He has also been a plenary speaker at the World Congress of Dermatology, Congress of Ibero-Latin American Dermatologists and the European Academy of Dermatology and Venereology. On a personal note, he is most proud of his role helping to raise four, productive, sane and debt-free adult children. Dr. Rosen is an avid numismatist, diehard Chicago Cub fan and life-long devotee of horror films. His most pressing bucket list item is a cameo role on the cable series "Walking Dead."

**David Rosmarin, M.D.**

Dr. Rosmarin is a clinical investigator and Vice-Chair for Research and Education at Tufts Medical Center focusing on clinical trials for inflammatory disorders of the skin. For his training, Dr. Rosmarin went to medical school at NYU, dermatology residency at Boston University-Tufts Combined training program, and fellowship at Brigham and Women's Hospital. Dr. Rosmarin joined Tufts Medical Center in 2013 focusing as a clinical trial investigator for atopic dermatitis. In 2016, Dr. Rosmarin became the Director of the Clinical Trials Unit in the Department of Dermatology at Tufts Medical Center and Program Director of the Residency Program. Notably, Dr. Rosmarin has served as the principle investigator for multiple investigator initiated trials for a topical JAK inhibitor for vitiligo, the use of an oral JAK inhibitor for discoid lupus, and for an anti-IL17 antibody to treat hidradenitis suppurativa. These studies have resulted

in Dr. Rosmarin becoming the PI for a multicentered trial evaluating topical ruxolitinib in vitiligo, which will likely lead to the first ever FDA indication for repigmenting vitiligo. Dr. Rosmarin is the first to use dupilumab for bullous pemphigoid which is now in a phase 3 program for an indication. His work on guselkumab and secukinumab for hidradenitis suppurativa has led to programs for development of an FDA indication as well. Clinically Dr. Rosmarin is nationally recognized and serves as a referral for physicians with difficult to manage inflammatory diseases such as atopic dermatitis. Dr. Rosmarin educates medical students, residents, and research fellows. He has expanded the Tufts Medical Residency Program from nine positions to eleven residents and mentors faculty in education and research.

This activity has been planned and implemented in accordance with the Essentials and Standards of the Connecticut State Medical Society through the joint sponsorship of CSEP and The Connecticut Dermatology & Dermatologic Surgery Society. CSEP is accredited by the CSMS to provide continuing medical education for physicians.

CSEP designates this educational activity for a maximum of 5.0 credit hours in category I credit toward the AMA Physicians Recognition Award.

Each physician should claim only those hours of credit that he/she spent in the activity.

## PRODUCT THEATER SPEAKER BIOS

**Michael Payette, M.D.**

Dr. Payette received his B.A. in Biochemistry from Dartmouth College in 2002. In 2008, Dr. Payette earned both his M.D. and M.B.A. from the University of Connecticut School of Medicine (UConn), where he continued to complete his dermatology residency in 2012. Prior to co-founding Central Connecticut Dermatology (CCD), Dr. Payette served as Chief Resident, Assistant Professor, and Associate Residency Program Director at UConn. Dr. Payette's specialties include general dermatology, inflammatory skin disorders (especially atopic dermatitis, psoriasis, and hidradenitis suppurativa), application of biologic medications, and diagnosis and treatment of skin cancer. Dr. Payette has served as a reviewer for several journals and has authored book chapters and numerous peer-reviewed publications. Dr. Payette has co-authored a medical textbook and is an associate editor for the Dermatology In-Review.

**Bruce E. Strober, M.D., PhD (CME Talk and Product Theater)**

Clinical Professor, Department of Dermatology

Yale University, New Haven, CT USA and Central Connecticut Dermatology Research, Cromwell, CT USA

Dr. Strober is Co-Scientific Director of the Corona Psoriasis Registry; Secretary-Treasurer of the International Psoriasis Council; Editor in Chief of the Journal of Psoriasis and Psoriatic Arthritis.

Dr. Strober earned both his medical degree and his doctorate from Columbia University College of Physicians and Surgeons in New York, New York. He completed his residency in dermatology in the Department of Dermatology, NYU School of Medicine.

He is board certified by the American Board of Dermatology and a Fellow in the American Academy of Dermatology.



**Lawrence Eichenfeld, M.D.**

Dr. Eichenfeld is Chief of Pediatric and Adolescent Dermatology at Rady Children’s Hospital, San Diego, Professor of Dermatology and Pediatrics and Vice-Chair of the Department of Dermatology at the University of California, San Diego. He received his medical degree from Mount Sinai School of Medicine in New York, was a pediatric resident and Chief Resident at Children’s Hospital of Philadelphia and completed his dermatology residency at the Hospital of the University of Pennsylvania. He is board-certified in dermatology, pediatric dermatology and pediatrics.

Dr. Eichenfeld has longstanding interests in atopic dermatitis, acne, psoriasis and other inflammatory skin conditions, as well as neonatal dermatology, vascular lesions, laser surgery and rare skin disorders. He has authored more than 400 journal articles, chapters, abstracts, and books and has served as the senior editor of Neonatal and Infant Dermatology, published by Elsevier, as well as The Eczemas. He served as Editor-in-Chief of Pediatric Dermatology for 12 years and serves on the editorial boards of multiple journals and periodicals. Dr. Eichenfeld has served in multiple leadership positions including Co-founder and co-Chair of the Pediatric Dermatology Research Alliance (PeDRA), Co-Chair of the American Academy of Dermatology Guidelines for Atopic Dermatitis, Co-chair of the American Acne and Rosacea Society/American Academy of Pediatrics Pediatric Acne Recommendations for Diagnosis and Treatment, member of the Expert Panel Member of the NIAID Guidelines for Diagnosis and Management of Food Allergy, Scientific Advisory Board of the National Eczema Association, and Director of the Rady/UCSD Eczema and Inflammatory Skin Disease Center. He has had leadership roles in guidelines and consensus statements for multiple disease states, including acne, rosacea, atopic dermatitis, psoriasis.

**Financial Disclosure**

**Speaker**

**Financial Interest Received**

Matthew Avram, M.D.	None
Mona Gohara, M.D.	None
Jennifer Huang, M.D.	None
Omar Ibrahim, M.D.	AbbVie, Accure Acne, Cutera, Lutronic, Blueberry Therapeutics, Organogenesis – <i>Advisory Board</i> ; AbbVie, Johnson & Johnson, Candesant, Cutera, Procter & Gamble, Unilever, Editas, Crisper Therapeutics, Intellia, Moderna, Beam Therapeutics, Pfizer, Revance, General Electric, Anthem, Viatrix, Vertex Pharmaceuticals, Vivene, Regeneron, AVAVA Medical, Accure Acne, Ginkgo Bioworks Holdings, Blueberry Therapeutics, Quthero – <i>Stockholder</i> ; American Society for Dermatologic Surgery, American Society for Lasers in Surgery and Medicine, Blueberry Therapeutics (Observer)
Joyce Lagnese, JD	None
Jeremy Moss, M.D.	AbbVie, Lilly, Regeneron, Amgen, Janssen, Dermavant, Sanofi- <i>Speaker’s Bureau</i>
David Rosmarin, M.D.	None
Ted Rosen, M.D.	None
Mona Shahriari, M.D.	AbbVie, Dermavant, Janssen, Lilly USA – <i>Speaker, Consultant, Investigator</i> ; Bristol Myers Squibb, Leo Pharma – <i>Speaker, Consultant</i> ; Cara Therapeutics, Novartis – <i>Consultant, Investigator</i> ; Arena Pharma, FIDE, Sanofi-Regeneron, UCB – <i>Consultant</i> ; Incyte – <i>Investigator</i> ; CorEviatas – <i>Investigator for Atopic Dermatitis and Psoriasis Registries</i>
Bruce Strober, M.D., PhD	AbbVie, Alamar, Alumis, Almirall, Amgen, Arcutis, Arena, Aristeia, Asana, Boehringer Ingelheim, Immunic Therapeutics, Kangpu Pharmaceuticals, Bristol-Myers-Squibb, Connect Biopharma, Dermavant, Evelo Biosciences, Janssen, Leo, Eli Lilly, Maruho, Meiji Seika Pharma, Mindera Health, Protagonist, Nimbus, Novartis, Pfizer, UCB Pharma, Sun Pharma, Regeneron, Sanofi-Genzyme, Union Therapeutics, Ventyx bio, vTv Therapeutics- <i>Consultant (honoraria)</i> ; Connect Biopharma, Mindera Health - <i>Stock Options</i> ; AbbVie, Arcutis, Dermavant, Eli Lilly, Incyte, Janssen, Regeneron, Sanofi-Genzyme - <i>Speaker</i> ; CorEviatas Psoriasis Registry - <i>Scientific Co-Director (consulting fee), Investigator</i> ; Journal of Psoriasis and Psoriatic Arthritis- <i>Editor-in-Chief (honorarium)</i>

**Competency Questions**

**Don’t Miss it! Rare but Important Pediatric Skin Conditions – Jennifer Huang, M.D.**

Question 1. The following tests should be obtained in a neonate with purpura:

- a. RPR
- b. skin biopsy
- c. Urine CMV PCR
- d. all of the above

Question 2. What organism has NOT been associated with a mucocutaneous hypersensitivity reaction?

- a. HSV
- b. Mycoplasma pneumonia
- c. VZV
- d. Chlamydia pneumonia

**Diversity In Dermatology: Moving the Needle – Mona Gohara, M.D.**

Question 1. Which one of the following is a form of unconscious bias:

- a. halo bias
- b. horns bias
- c. affinity bias
- d. all of the above

Question 2. Which of the following is a test to identify one’s own biases

- a. Implicit Association Test
- b. Briggs Myers Personality Test
- c. SWOT analysis
- d. none of the above

**New Anti-infectives and Why We Need Them – Ted Rosen, M.D.**

Question 1. Abametapir is a new agent recently approved to treat

- a. Public lice
- b. Scabies

- c. Head lice
- d. Leishmaniasis
- e. Demodex

- Question 2. Which statement is true regarding Omadacycline?
- a. It is expected to be effective for infected human bite wounds
  - b. Resistance develops easily
  - c. It must be given intravenously
  - d. It belongs to a new drug class: aminomethylcycline
  - e. It is related to topical retapamulin

**An Update on the Treatment of Vitiligo – David Rosmarin, M.D.**

- Question 1. Which anatomic region is easiest to repigment?
- a. face
  - b. hands
  - c. feet
  - d. trunk
  - e. arms

- Question 2. Which feature indicates that vitiligo is active?
- a. koebner phenomenon
  - b. confetti lesions
  - c. trichrome vitiligo
  - d. all of the above

**Update on Psoriasis Therapies – Bruce Strober, M.D.**

- Question 1. Deucravacitinib is a small molecule oral drug that directly inhibits:
- a. IL-17
  - b. TYK2
  - c. p19
  - d. p40
  - e. JAK1

- Question 2. Tapinarof is topical drug that:
- a. directly inhibits IL-17
  - b. activates the aryl hydrocarbon receptor
  - c. directly inhibits p19
  - d. directly inhibits p40
  - e. directly inhibits TNF-α

- Question 3. Which of the following biologics is FDA-approved for the treatment of active psoriatic arthritis:
- a. tildrakizumab
  - b. risankizumab
  - c. guselkumab
  - d. risankizumab
  - e. bimekizumab

**Outcome Measurements**

Name: \_\_\_\_\_


- 1. Has this symposium changed the way you will care for patients?  Yes  No
- 2. Do you believe this symposium will have a positive effect on patient surgical or clinical outcomes?  
 Yes  No
- 3. Can you offer other speakers or topics that will provide information to improve clinical outcomes at the next meeting?  Yes  No \_\_\_\_\_

**Education Mission Statement**

We are committed to advancing the highest standards of skin care through continuing education activities. The Connecticut Dermatology and Dermatologic Surgery Society Semi-annual Scientific Education Programs are dedicated to improving and protecting our patient's skin health by presenting advances in the diagnosis and treatment of skin disease. Our target audience includes dermatologists and their staff, including office managers and medical assistants. Activities range from didactic lectures to participatory activities, and whenever possible are approved for CME credit. We expect that our audience will incorporate best practices, as presented, into their daily practice. Specific competency, performance and patient outcome goals that will result from the program will be proposed by the presenters and evaluated by the participants.

(Reviewed 1//14/20  
by the Executive Committee)

# Connecticut Dermatology and Dermatologic Surgery Society Virtual Series Program



January 21, 28, February 4, 2021

Member Physician: \_\_\_\_\_

Address: \_\_\_\_\_

Telephone: \_\_\_\_\_ FAX: \_\_\_\_\_

Email: \_\_\_\_\_

*Email is required to send link*

\_\_\_\_\_ Attending                      \_\_\_\_\_ Not Attending

\_\_\_\_\_ **CDDSS Member Physician - \$25.00 if registered by December 31, 2020**

**After December 31, 2020 \$35\***

\_\_\_\_\_ **Non-Member Physician - \$50.00\***

\_\_\_\_\_ **PA or APRN employed by Member Physician - \$50.00\***

\_\_\_\_\_ **\*All Registrations after December 31, please add \$20.00 Late Fee**

This activity has been planned and implemented in accordance with the Essentials and Standards of the Connecticut State Medical Society through the joint sponsorship of CSEP and The Connecticut Dermatology & Dermatologic Surgery Society. CSEP is accredited by the CSMS to provide continuing medical education for physicians. CSEP designates this educational activity for a maximum of 5.0 credit hours in category I credit toward the AMA Physicians Recognition Award. Each physician should claim only those hours of credit that he/she spent in the activity.

Suggested topics or speakers that you would like CDS to offer: \_\_\_\_\_

\_\_\_\_\_  
\_\_\_\_\_


Please mail this form to:

CDS, P.O. Box 1079, Litchfield, CT 06759 Tel. 860-567-4911



or fax to: 860-567-3591 or email Debbie Osborn at [debbieosborn36@yahoo.com](mailto:debbieosborn36@yahoo.com)

Check #: \_\_\_\_\_ Received: \_\_\_\_\_ Amount: \_\_\_\_\_





P O Box 1079  
Litchfield, CT 06759





**Credit Card Payment Form**  
**Dermatology Program**  
PO BOX 854, LITCHFIELD, CT 06759

This portion can be faxed back to (860) 567-3591 or Email [debbieosborn36@yahoo.com](mailto:debbieosborn36@yahoo.com)

\_\_\_\_\_ Visa                      \_\_\_\_\_ Mastercard                      \_\_\_\_\_ American Express

\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
(16 digit card number)

\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
(Expiration date)

Security Codes

\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
\*3 digit # that appears on the back of the MC/VISA card

\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_/\_\_\_\_\_  
4 digit # that appears on the front of AMEX card

Names of Attendees

_____	_____
_____	_____
_____	_____
_____	_____

\$ \_\_\_\_\_ Total amount charged

\_\_\_\_\_  
(Card holders name)

\_\_\_\_\_  
(Card holders signature)

\_\_\_\_\_  
(Card holders address)

\_\_\_\_\_  
(Group Practice name)

\* \_\_\_\_\_  
(City - State - Zip) Need Zip code from card billing address to process

CT Dermatology, 26 Sally Burr Road • PO Box 1079 • Litchfield, CT 06759  
Fax 860-567-3591 email [debbieosborn36@yahoo.com](mailto:debbieosborn36@yahoo.com)

***“M.D. Makes the Difference”***

Please fill out completely!

\*These numbers are needed to run payment through with a merchant discount